Baseline characteristics of subjects (n=16) completing the study
| Age, years | 42.0±10.3 |
| Disease duration, years | 9.1±6.5 |
| BMI, kg/m2 | 28.2±5.2 |
| Race/ethnicity, n (%) | |
| White | 2 (12.5%) |
| African-American | 3 (18.8%) |
| Asian | 3 (18.8%) |
| Hispanic | 8 (50%) |
| Gender, n (%) | |
| Female | 16 (100%) |
| SELENA-SLEDAI | 1.4±1.9 |
| SLICC/ACR DI | 0.8±1.2 |
| Drugs, n (%) | |
| Glucocorticoids | 11 (68.7%) |
| Antimalarials | 15 (93.7%) |
| Azathioprine | 5 (31.2%) |
| Methotrexate | 2 (12.5%) |
| Mycophenolate mofetil | 6 (37.5%) |
Values are means±SD or count and percentage of total sample, n=number of patients.
BMI, body mass index; SELENA-SLEDAI, Safety of Estrogen in Lupus Erythematosus, National Assessment modification of Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.